Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy.
Prostate Cancer Prostatic Dis., Sep;15(3):289-95 (2012)
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
BJU international (2013)
Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF.
Clinical cancer research : an official journal of the American Association for Cancer Research, 19, 1290-9 (2013)
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.
Cancer journal (Sudbury, Mass.), 19, 50-8 (2013)
Ipilimumab in prostate cancer.
Expert opinion on biological therapy, 13, 303-13 (2013)
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer.
International journal of cancer. Journal international du cancer (2013)
Progress in prostate cancer imaging.
Urologic oncology, 30, 938-9 (2012)
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity.
Oncoimmunology, 1, 1167-1168 (2012)
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Journal of the National Cancer Institute, 104, 1106; author reply 1109-12 (2012)
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 53, 1175-84 (2012)
Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer.
Journal of the National Comprehensive Cancer Network : JNCCN, 10, 1505-12 (2012)
Therapeutic vaccines: The ultimate personalized therapy?
Human vaccines & immunotherapeutics, 9, 219-21 (2013)
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.
Blood, 120, 3030-8 (2012)
Toward an off-the-shelf vaccine for B-cell malignancies.
Blood, 120, 1539-40 (2012)
Clinical evaluation of TRICOM vector therapeutic cancer vaccines.
Seminars in oncology, 39, 296-304 (2012)
Poxviral vectors for cancer immunotherapy.
Expert opinion on biological therapy, 12, 463-78 (2012)
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
The lancet oncology, 13, 501-8 (2012)
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.
Cancer immunology, immunotherapy : CII, 61, 109-17 (2012)